Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction.
The objective of this retrospective study is to evaluate the effectiveness of short term intracavernous pharmacotherapy in the treatment of persistent psychogenic impotence. The study included 153 patients evaluated within an Andrology clinic in a general hospital working in close relation to three psychiatry clinics in three hospitals. Patients underwent an average of two office sessions of intracavernous injections for the selection of the appropriate intracavernous agent and dose, and for self injection training. Of the 153 patients included in our study 98 (64%) needed the injection for less than three months, only 18 (12%) patients needed the injections up to one year. We concluded that intracavernous self injection of vasoactive drugs is an effective alternative in the treatment of men with persistent psychogenic impotence when sex therapy is unsuccessful.
Ghanem
H
H
Department of Andrology, Cairo University, Jeddah, Saudi Arabia.
Sherif
T
T
Adbel-Gawad
T
T
Asaad
T
T
D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use; D001007:Anxiety; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000523:psychology*; D006801:Humans; D008297:Male; D008393:Marriage; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage / Q000627:therapeutic use; D010409:Penile Diseases; D010410:Penile Erection; D010413:Penis / Q000187:drug effects; D010646:Phentolamine / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D012646:Self Administration; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use*
D014665:Vasodilator Agents; D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine